Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756515 | 0.89 | PRKDC (0.59) | PRKDCPIK3CARAB9ASMN1; SMN2MAPT | |
| SCHEMBL3755187 | 0.86 | PRKDC (0.59) | PRKDCPIK3CARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3755774 | 0.86 | PIK3CA (0.54) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3754705 | 0.85 | PRKDC (0.53) | PRKDCPIK3CA | |
| SCHEMBL3754528 | 0.85 | PRKDC (0.57) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3754238 | 0.84 | PRKDC (0.56) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3749833 | 0.84 | PRKDC (0.56) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3754519 | 0.84 | PRKDC (0.62) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3756362 | 0.84 | PRKDC (0.57) | PRKDCPIK3CAGPR142 | |
| SCHEMBL3762593 | 0.83 | PRKDC (0.54) | PRKDCPIK3CARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885PIK3CA 16/4885RAB9A 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.